fda glp 1 compounding The FDA recently published updates clarifying policies for compounding drug manufacturers producing Compounded GLP-1s: Why doctors worry

The primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and 701 of the 8801 patients (8.0%) in the placebo group (Lincoff et al

"Telogen effluvium: new concepts and review." Arch Dermatol , 1993

Many are trying to address this by expanding their range of protein-rich products and creating GLP-1 companion products, but it probably wont be enough

GOAL: To give the pharmacist a clinical and pharmacotherapeutic overview of dipeptidyl peptidase-4 (DPP-4) inhibitors available in the United States for treatment of type 2 diabetes

Andrew Dillin, quoted in this New York Times article on rapamycin, thinks not: Why take risks with unproven benefits? he told The Times

Diabetologia 54, 30933100